PMID- 17586306
OWN - NLM
STAT- MEDLINE
DCOM- 20070703
LR  - 20231120
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
VI  - 369
IP  - 9579
DP  - 2007 Jun 23
TI  - Neuroblastoma.
PG  - 2106-20
AB  - The clinical hallmark of neuroblastoma is heterogeneity, with the likelihood of 
      cure varying widely according to age at diagnosis, extent of disease, and tumour 
      biology. A subset of tumours will undergo spontaneous regression while others 
      show relentless progression. Around half of all cases are currently classified as 
      high-risk for disease relapse, with overall survival rates less than 40% despite 
      intensive multimodal therapy. This Seminar focuses on recent advances in our 
      understanding of the biology of this complex paediatric solid tumour. We outline 
      plans for the development of a uniform International Neuroblastoma Risk Group 
      (INRG) classification system, and summarise strategies for risk-based therapies. 
      We also update readers on new discoveries related to the underlying molecular 
      pathogenesis of this tumour, with special emphasis on advances that are 
      translatable to the clinic. Finally, we discuss new approaches to treatment, 
      including recently discovered molecular targets that might provide more effective 
      treatment strategies with the potential for less toxicity.
FAU - Maris, John M
AU  - Maris JM
AD  - Children's Hospital of Philadelphia and University of Pennsylvania School of 
      Medicine, Philadelphia, PA 19104-4318, USA. maris@chop.edu
FAU - Hogarty, Michael D
AU  - Hogarty MD
FAU - Bagatell, Rochelle
AU  - Bagatell R
FAU - Cohn, Susan L
AU  - Cohn SL
LA  - eng
GR  - P01-CA97323/CA/NCI NIH HHS/United States
GR  - P30CA60553/CA/NCI NIH HHS/United States
GR  - R01-CA78545/CA/NCI NIH HHS/United States
GR  - R01-CA87847/CA/NCI NIH HHS/United States
GR  - R01-NS049814/NS/NINDS NIH HHS/United States
GR  - U10-CA98543/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
SB  - IM
MH  - Gene Expression Profiling/*methods
MH  - Humans
MH  - *Neuroblastoma/genetics/physiopathology/therapy
MH  - Prognosis
RF  - 209
EDAT- 2007/06/26 09:00
MHDA- 2007/07/04 09:00
CRDT- 2007/06/26 09:00
PHST- 2007/06/26 09:00 [pubmed]
PHST- 2007/07/04 09:00 [medline]
PHST- 2007/06/26 09:00 [entrez]
AID - S0140-6736(07)60983-0 [pii]
AID - 10.1016/S0140-6736(07)60983-0 [doi]
PST - ppublish
SO  - Lancet. 2007 Jun 23;369(9579):2106-20. doi: 10.1016/S0140-6736(07)60983-0.